Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for small–cell lung cancer as well as unresectable NSCLC.
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining dose density and intensity as well as monitoring toxicity.
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in bacillus Calmette-Guérin–unresponsive bladder cancer with high risk for disease progression.
Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations and novel approaches in lung cancer.
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses managing toxicities of immunotherapy, including neurotoxicity, and treating beyond acute adverse events.
